Pemgarda likely effective against circulating SARS-CoV-2 variants, says FDA

According to an FDA statement released on September 26, the monoclonal antibody pemivibart (Pemgarda) is likely to retain adequate neutralization activity against KP.3.1.1, which means it may be effective for pre-exposure prophylaxis of COVID-19 caused by this variant. Based on current CDC Nowcast estimates and variant spike receptor binding domain similarity to tested variants, FDA says it anticipates Pemgarda will retain activity against the currently circulating variants in the U.S. Tap for more details ...